70.4 F
New York
Friday, June 9, 2023



Thrombolex, Inc. – BASHIR™ Endovascular Catheters Show Dramatic Reduction in Thromboembolic Occlusions

Related Articles

Nebraska Medicine’s Doctor Corrigan McBride First to Introduce Endolumik’s New “Safer Technology” Surgical Tool

Omaha, NE, June 09, 2023 --(PR.com)-- Endolumik, an innovator in minimally-invasive surgical devices, today announced that its fluorescence guided Gastric Calibration Tube has begun commercial...

Colorado Governor Jared Polis Signs Radon Disclosure Bill into Law

Denver, CO, June 09, 2023 --(PR.com)-- The Radon Disclosure Bill for Residential Property (SB23-206) was signed into law on June 5, 2023 by Governor Jared...

Rocky Mountain Hospital for Children Attains National Verification from the American College of Surgeons

Denver, CO, June 09, 2023 --(PR.com)-- Denver-area center meets all criteria as a Level 1 Children’s Surgery Center, which recognizes its dedication to providing optimal...
New Britain, PA, January 17, 2022 –(PR.com)– THROMBOLEX, INC. announced positive results from the pre-specified interim analysis of the first 62 evaluable pulmonary embolism (PE) patients enrolled in the investigational RESCUE Trial. RESCUE is a prospective multicenter, single-arm pivotal trial evaluating patient outcomes after treatment of acute intermediate risk PE. This pivotal trial is scheduled to enroll at least 100 evaluable patients. The trial is evaluating the efficacy and safety of the BASHIR™ and BASHIR™ S-B Endovascular Catheters in the treatment of acute PE under an Investigational Device Exemption (IDE) from the FDA. An analysis of the interim data was presented today at the Late Breaking Clinical Trials session at the ISET Conference in Miami by Dr. Ripal Gandhi, of the Miami Cardiac and Vascular Institute, on behalf of the RESCUE investigators.

During this session, Dr. Gandhi reported new detailed data on the…

Read more…

Popular Articles